[1] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023; 79, 1542−56. doi:  10.1016/j.jhep.2023.06.003
[2] Miao L, Targher G, Byrne CD, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab, 2024; 35, 697−707. doi:  10.1016/j.tem.2024.02.007
[3] GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of Hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol, 2022; 7, 796−829. doi:  10.1016/S2468-1253(22)00124-8
[4] Zhang CH, Cheng YF, Zhang S, et al. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int, 2022; 42, 2029−41. doi:  10.1111/liv.15251
[5] Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol, 2023; 79, 516−37. doi:  10.1016/j.jhep.2023.03.017
[6] Jiang DX, Chen C, Liu XX, et al. Concurrence and impact of hepatic steatosis on chronic Hepatitis B patients: a systematic review and meta-analysis. Ann Transl Med, 2021; 9, 1718. doi:  10.21037/atm-21-3052
[7] Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol, 2018; 68, 526−49. doi:  10.1016/j.jhep.2017.09.016
[8] Wang ZY, Zhao XY, Chen SH, et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin Gastroenterol Hepatol, 2021; 19, 788-96. e4.
[9] Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017; 66, 1138−53. doi:  10.1136/gutjnl-2017-313884
[10] Hsu YC, Huang DQ, Nguyen MH. Global burden of Hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol, 2023; 20, 524−37. doi:  10.1038/s41575-023-00760-9
[11] Liu T, Song CH, Zhang YC, et al. Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: a prospective cohort study. Int J Cancer, 2022; 150, 1018−28. doi:  10.1002/ijc.33891
[12] Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2021; 6, 903−13. doi:  10.1016/S2468-1253(21)00308-3
[13] Wang YQ, Xiong JP, Niu M, et al. Hepatitis B virus and the risk of coronary heart disease: a comprehensive systematic review and meta-analyses of observational studies. Int J Cardiol, 2018; 265, 204−9. doi:  10.1016/j.ijcard.2018.04.059
[14] Mao XH, Cheung KS, Peng CZ, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology, 2023; 77, 1735−45. doi:  10.1002/hep.32792
[15] Ayada I, Li JJ, Brouwer WP, et al. Impact of chronic Hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma. Hepatol Int, 2024; 18, 1053−5. doi:  10.1007/s12072-024-10639-9
[16] Yip TCF, Wong VWS, Wong GLH. Does hepatic steatosis impact chronic Hepatitis B? Hepatology, 2023; 77, 1478-81.
[17] Disease Prevention and Control Bureau of the Ministry of Health. Report on national Hepatitis B seroepidemiological survey of China 2010. People’s Medical Publishing House. 2011.
[18] Wang AX, Liu XX, Guo XH, et al. Resting heart rate and risk of hypertension: results of the Kailuan cohort study. J Hypertens, 2014; 32, 1600−5. doi:  10.1097/HJH.0000000000000230
[19] Lee DH, Rezende LFM, Ferrari G, et al. Physical activity and all-cause and cause-specific mortality: assessing the impact of reverse causation and measurement error in two large prospective cohorts. Eur J Epidemiol, 2021; 36, 275−85. doi:  10.1007/s10654-020-00707-3
[20] Wang C, Yuan Y, Zheng MY, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol, 2020; 75, 2921−30.
[21] Wang XM, Wu SL, Yuan XJ, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab, 2022; 107, e745−55. doi:  10.1210/clinem/dgab644
[22] Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009; 120, 1640−5. doi:  10.1161/CIRCULATIONAHA.109.192644
[23] Jacobson TA, Maki KC, Orringer CE, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol, 2015; 9, S1-122. e1.
[24] Echouffo-Tcheugui JB, Perreault L, Ji LN, et al. Diagnosis and management of prediabetes: a review. JAMA, 2023; 329, 1206−16. doi:  10.1001/jama.2023.4063
[25] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 2004; 363, 157−63. doi:  10.1016/S0140-6736(03)15268-3
[26] Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med, 2020; 18, 361. doi:  10.1186/s12916-020-01824-2
[27] da Silva A, Caldas APS, Hermsdorff HHM, et al. Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care. Cardiovasc Diabetol, 2019; 18, 89. doi:  10.1186/s12933-019-0893-2
[28] Andersen PK, Geskus RB, De Witte T, et al. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol, 2012; 41, 861−70. doi:  10.1093/ije/dyr213
[29] Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res, 2021; 51, 1115−28. doi:  10.1111/hepr.13685
[30] Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA, 2019; 321, 602−3. doi:  10.1001/jama.2018.21554
[31] Wong YJ, Nguyen VH, Yang HI, et al. Impact of fatty liver on long-term outcomes in chronic Hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol, 2023; 29, 705−20. doi:  10.3350/cmh.2023.0004
[32] Houghton D, Zalewski P, Hallsworth K, et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol, 2019; 70, 1203−13. doi:  10.1016/j.jhep.2019.01.035
[33] Huang SC, Su TH, Tseng TC, et al. Pre-existing and new-onset metabolic dysfunctions increase cirrhosis and its complication risks in chronic Hepatitis B. Am J Gastroenterol, 2025; 120, 401−9. doi:  10.14309/ajg.0000000000002915
[34] Huang SC, Su TH, Tseng TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic Hepatitis B. Hepatol Int, 2023; 17, 1139−49. doi:  10.1007/s12072-023-10545-6
[35] Kalligeros M, Henry L, Younossi ZM. Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism, 2024; 160, 156004. doi:  10.1016/j.metabol.2024.156004
[36] Huang SC, Su TH, Tseng TC, et al. All-cause and cause-specific mortality in patients with chronic Hepatitis B and concurrent steatotic liver disease. J Hepatol, 2024; 83, 43−51.
[37] Hu DQ, Wang HW, Wang H, et al. Non-alcoholic hepatic steatosis attenuates Hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int, 2018; 12, 438−46. doi:  10.1007/s12072-018-9877-7
[38] Liu QC, Mu MY, Chen H, et al. Hepatocyte steatosis inhibits Hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem, 2022; 477, 2481−91. doi:  10.1007/s11010-021-04143-z
[39] Liu WY, Huang SS, Ji HS, et al. From "Burnt-Out" to "Burning-Out": capturing liver fat loss in patients with advanced metabolic dysfunction-associated steatotic liver disease from a dynamic perspective. Gastroenterology, 2025; 169, 326-36. e4.
[40] Mantovani A, Byrne CD, Benfari G, et al. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol, 2022; 79, 180−191.
[41] Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol, 2021; 6, 578−88. doi:  10.1016/S2468-1253(21)00020-0
[42] Thong VD, Quynh BTH. Correlation of serum transaminase levels with liver fibrosis assessed by transient elastography in vietnamese patients with nonalcoholic fatty liver disease. Int J Gen Med, 2021; 14, 1349−55. doi:  10.2147/IJGM.S309311
[43] Zhang MY, Chen SY, Wu XN, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection. J Med Virol, 2023; 95, e29156. doi:  10.1002/jmv.29156
[44] Han E, Han KD, Lee YH, et al. Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality. Cardiovasc Diabetol, 2025; 24, 289. doi:  10.1186/s12933-025-02824-3
[45] Dong H, Sun YZ, Nie LLX, et al. Metabolic memory: mechanisms and diseases. Signal Transduct Target Ther, 2024; 9, 38. doi:  10.1038/s41392-024-01755-x
[46] Zhou BG, Jiang X, She Q, et al. Association of MASLD with the risk of extrahepatic cancers: a systematic review and meta-analysis of 18 cohort studies. Eur J Clin Invest, 2024; 54, e14276. doi:  10.1111/eci.14276
[47] Celsa C, Pennisi G, Tulone A, et al. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2025; 10, 998−1012. doi:  10.1016/S2468-1253(25)00188-8
[48] Mantovani A, Lonardo A, Stefan N, et al. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers. Metabolism, 2024; 160, 156014. doi:  10.1016/j.metabol.2024.156014
[49] Lonardo A, Stefan N, Mantovani A. Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. Trends Endocrinol Metab, 2025; 36, 610−3. doi:  10.1016/j.tem.2024.12.009
[50] Zhang SH, Wang C, Liu B, et al. Cost-effectiveness of expanded antiviral treatment for chronic Hepatitis B virus infection in China: an economic evaluation. Lancet Reg Health West Pac, 2023; 35, 100738.
[51] Lu FM, Zhuang H. Management of Hepatitis B in China. Chin Med J, 2009; 122, 3−4. doi:  10.5005/jp/books/11250_28
[52] Kalafateli M, Forlano R, Barnes E, et al. Risk factors of metabolic dysfunction-associated steatotic liver disease in a cohort of patients with chronic Hepatitis B. Clin Gastroenterol Hepatol, 2026; 24, 701-12. e8.
[53] Anderson RT, Choi HSJ, Lenz O, et al. Association between seroclearance of Hepatitis B surface antigen and long-term clinical outcomes of patients with chronic Hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2021; 19, 463−72. doi:  10.1016/j.cgh.2020.05.041
[54] Kim H, Kim JY, Choi HB, et al. Antiviral therapy reduces dyslipidemia and cardiovascular risk in chronic Hepatitis B: TDF as the most effective agent. J Med Virol, 2025; 97, e70584. doi:  10.1002/jmv.70584
[55] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of Hepatitis B virus infection. J Hepatol, 2025; 83, 502−83. doi:  10.1016/j.jhep.2025.03.018
[56] Zelber-Sagi S, Schonmann Y, Weinstein G, et al. Liver fibrosis marker FIB-4 is associated with hepatic and extrahepatic malignancy risk in a population-based cohort study. Liver Int, 2025; 45, e70139. doi:  10.1111/liv.70139
[57] Bellini MI, Urciuoli I, Del Gaudio G, et al. Nonalcoholic fatty liver disease and diabetes. World J Diabetes, 2022; 13, 668−82. doi:  10.4239/wjd.v13.i9.668
[58] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts, 2024; 17, 374−444. doi:  10.1159/000539371
[59] Li YZ, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020; 369, m997. doi:  10.1136/bmj.m997
[60] Wang ZW, Chen Z, Zhang LF, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation, 2018; 137, 2344−56. doi:  10.1161/CIRCULATIONAHA.117.032380
[61] Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol, 2019; 16, 203−12. doi:  10.1038/s41569-018-0119-4
[62] Han BF, Zheng RS, Zeng HM, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024; 4, 47−53.
[63] Gao JL, Li YH, Zhang YJ, et al. Severity and remission of metabolic dysfunction-associated fatty/steatotic liver disease with chronic kidney disease occurrence. J Am Heart Assoc, 2024; 13, e032604. doi:  10.1161/JAHA.123.032604